Allergy to carbamazepine: Parallel in vivo and in vitro detection

Epilepsia

Volumn 37, Issue 11, 1996, Pages 1093-1099

  Troost, Roger J J ^a,c   Van Parys, Johan A P ^b   Hooijkaas, Herbert ^a   Van Joost, Theodoor ^a   Benner, Robbert ^a   Prens, Errol P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Instituut voor Epilepsiebestrijding   (Netherlands)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Carbamazepine; Cross reactivity; Drug hypersensitivity; Lymphocyte transformation; Oxcarbazepine; Patch tests

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DRUG METABOLITE; OXCARBAZEPINE;

ADOLESCENT; ADULT; AGED; ALLERGY TEST; ARTICLE; CHILD; CONTROLLED STUDY; CROSS ALLERGY; DRUG HYPERSENSITIVITY; EPILEPSY; FEMALE; HUMAN; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PATCH TEST; PRIORITY JOURNAL; SKIN TEST;

EID: 0029802174     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1996.tb01030.x     Document Type: Article

References (48)

1. Sillanpaa M. Carbamazepine: pharmacology and clinical uses. Acta Neurol Scand Suppl 1981;88:1-202.
2. Pelekanos J, Camfield P, Camfield C, Gordon K. Allergic rash due to antiepileptic drugs: clinical features and management. Epilepsia 1991;32:554-9.
3. Konishi T, Naganuma Y, Kongo K, Murakami M, Yamatani M, Okada T. Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 1993;152:605-8.
4. Jones M, Fernandez HJ, Dorado JM, Sols M, Ruiz M, Garcia DA. Epicutaneous test in carbamazepine cutaneous reactions. Dermatology 1994;188:18-20.
5. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in pediatric epilepsy. Dev Med Child Neurol 1995;37:97-108.
6. Bastuji Garin S, Zahedi M, Guillaume JC, Roujeau JC. Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients. Age Ageing 1993;22:450-6.
7. Leenutaphong V, Sivayathorn A, Suthipinittharm P, Sunthonpalin P. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol 1993;32:428-31.
8. Friedmann PS, Strickland I, Pirmohamed M, Park BK. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994;130:598-604.
9. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
10. Kramer G, Bork K. Dermatologische Nebenwirkungen von Carbamazepin. In: Kramer G, Hopf HC, eds. Carbamazepinen in der Neurologie. Stuttgart: Thieme, 1987:130-41.
11. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988;82:1826-32.
12. Pirmohamed M, Graham A, Roberts P, et al. Carbamazepine hypersensitivity: assessment of clinical and in vitro chemical crossreactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991;32:741-9.
13. Drory VE, Korczyn AD. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin Neuropharmacol 1993;16:19-29.
14. De Ponti F, Lecchini S, Cosentino M, Castelletti CM, Malesci A, Frigo GM. Immunological adverse effects of anticonvulsants: what is their clinical relevance? Drug Safety 1993;8:235-50.
15. O'Connor CR, Schraeder PL, Kurland AH, O'Connor WH. Evaluation of the mechanisms of antiepileptic drug-related chronic leukopenia. Epilepsia 1994;35:149-54.
16. DeSwarte RD. Drug allergy: an overview. Clin Rev Allergy 1986; 4:143-69.
17. Halpern B, Amache N. Diagnosis of drug allergy in vitro with the lymphocyte transformation test. J Allergy 1967;40:168-81.
18. Virolainen M. Blast transformation in vivo and in vitro in carbamazepine hypersensitivity. Clin Exp Immunol 1971;9:429-35.
19. Houwerzijl J, de Gast GC, Nater JP, Esselink MT, Nieweg HO. Lymphocyte-stimulation tests and patch tests to carbamazepine hypersensitivity. Clin Exp Immunol 1977;29:272-7.
20. Zakrzewska JM, Ivanyi L. In vitro lymphocyte proliferation by carbamazepine, carbamazepine-10,11-epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988;82:110-5.
21. Troost RJJ, Prens EP, Van Parys JAP, Benner R, Van Joost T. Comparison of patch testing and lymphocyte proliferation assay in patients with suspected drug allergy [Abstract]. J Invest Dermatol 1991;96:1027.
22. Horneff G, Lenard HG, Wahn V. Severe adverse reaction to carbamazepine: significance of humoral and cellular reactions to the drug. Neuropediatrics 1992;23:272-5.
23. Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993;29:254-7.
24. Calkin JM, Maibach HI. Delayed hypersensitivity drug reactions diagnosed by patch testing. Contact Dermatitis 1993;29:223-33.
25. Scerri L, Shall L, Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome - pathogenic and diagnostic considerations. Clin Exp Dermatol 1993;18:540-2.
26. Chadwick D, Shaw MD, Foy P, Rawlins MD, Turnbull DM. Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. J Neurol Neurosurg Psychiatry 1984;47:642-4.
27. Warnock JK, Knesevich JW. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 1988;145:425-30.
28. Fisher AA. Contact dermatitis. 3rd ed. Philadelphia: Lea & Febiger, 1988:954.
29. Jensen PK, Gram L, Schmutz M. Oxcarbazepine [Review]. Epilepsy Res Suppl 1991;3:135-40.
30. Hui SL, Walter SD. Estimating the error rates of diagnostic tests. Biometrics 1980;36:167-71.
31. Altman DG. Practical statistics in medical research. London: Chapman & Hall, 1992.
32. Tomson T, Bertilsson L. Kinetics, metabolism and effects of carbamazepine-10,11-epoxide in man [Review]. Epilepsy Res Suppl 1991;3:177-81.
33. Lertratanangkoon K, Horning MG. Metabolism of carbamazepine. Drug Metab Dispos 1982;10:1-10.
34. Houtkooper MA, Lammertsma A, Meyer JW, et al. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine? Epilepsia 1987;28:693-8.
35. Reinikainen KJ, Keranen T, Halonen T, Komulainen H, Riekkinen PJ. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987;1:284-9.
36. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic outpatients in oxcarbazepine treatment. Acta Neurol Scand 1993;87:224-7.
37. Kalviainen R, Keranen T, Riekkinen PJS. Place of newer antiepileptic drugs in the treatment of epilepsy. Drugs 1993;46:1009-24.
38. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance [Review]. Epilepsia 1994; 35:14-9.
39. Dam M. Practical aspects of oxcarbazepine treatment. Epilepsia 1994;35:23-5.
40. Gram L. Clinical experience with oxcarbazepine [Review]. Epilepsia 1994;35:21-2.
41. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine [Review]. Epilepsia 1994;35:10-3.
42. Van Parys JAP, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res 1994;19:79-85.
43. Berg PA, Becker W. The lymphocyte transformation test - a debated method for the evaluation of drug allergic hepatic injury. J Hepatol 1995;22:115-8.
44. Shear NH. Diagnosing cutaneous adverse reactions to drugs. Arch Dermatol 1990;126:94-7.
45. Smith H, Newton R. Adverse reactions to carbamazepine managed by desensitisation [Letter]. Lancet 1985;1:753.
46. Eames P. Adverse reactions to carbamazepine managed by desensitisation [Letter]. Lancet 1989;1:509-10.
47. Watts D, Bird J. Oxcarbazepine sensitivity treated by desensitisation [Letter]. J Neurol Neurosurg Psychiatry 1991;1:54.
48. Hermle L, Spitzer M. Successful hyposensitization treatment of a patient with schizoaffective psychosis and carbamazepine allergy [German]. Nervenarzt 1993;64:208-10.